Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life

Cary A. Presant, Mark S. Soloway, Sol S. Klioze, Alun Yakabow, Seth N. Presant, Rafael G. Mendez, Peter S. Kennedy, Melody R. Wyres, Virginia L. Naessig, Barbara Todd, Charles L. Wiseman, Armand Bouzaglou, Barton Tanenbaum, Daniel Eventov

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stage C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient-scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.

Original languageEnglish (US)
Pages (from-to)1713-1716
Number of pages4
JournalCancer
Volume59
Issue number10
DOIs
StatePublished - May 15 1987

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Presant, C. A., Soloway, M. S., Klioze, S. S., Yakabow, A., Presant, S. N., Mendez, R. G., Kennedy, P. S., Wyres, M. R., Naessig, V. L., Todd, B., Wiseman, C. L., Bouzaglou, A., Tanenbaum, B., & Eventov, D. (1987). Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life. Cancer, 59(10), 1713-1716. https://doi.org/10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8